Table 1.
Demographic, clinical symptoms, comorbidities, and hospitalization information of individuals with the severe acute respiratory syndrome (SARS) due to SARS-CoV2 infection in Brazil*
| Data | Category | N (%) |
|---|---|---|
| Sex | Female |
261 445 (44.6%) |
|
|
Male |
324 210 (55.4%) |
| Age – years old | <1 |
2833 (0.5%) |
| 1 to 12 |
5376 (0.9%) |
|
| 13 to 24 |
10 647 (1.8%) |
|
| 25 to 60 |
261 523 (44.7%) |
|
| 61 to 72 |
148 509 (25.4%) |
|
| 73 to 85 |
118 657 (20.3%) |
|
|
|
+85 |
38 110 (6.5%) |
| Race | White |
309 646 (52.9%) |
| Black |
31 872 (5.4%) |
|
| Asian |
7108 (1.2%) |
|
| Individuals with multiracial background |
235 108 (40.1%) |
|
|
|
Indigenous |
1921 (0.3%) |
| Geographic zone | Urban |
557 571 (95.2%) |
| Rural |
26 215 (4.5%) |
|
|
|
Peri-urban |
1869 (0.3%) |
| Lived in a place with a Flu outbreak† | Yes |
121 079 (20.7%) |
|
|
No |
464 576 (79.3%) |
| Nosocomial infection | Yes |
11 291 (1.9%) |
|
|
No |
574 364 (98.1%) |
|
Clinical symptoms
| ||
| Fever | Yes |
412 083 (70.4%) |
|
|
No |
173 572 (29.6%) |
| Cough | Yes |
463 476 (79.1%) |
|
|
No |
122 179 (20.9%) |
| Sore throat | Yes |
178 618 (30.5%) |
|
|
No |
407 037 (69.5%) |
| Dyspnoea | Yes |
471 959 (80.6%) |
|
|
No |
113 696 (19.4%) |
| Respiratory discomfort | Yes |
427 694 (73.0%) |
|
|
No |
157 961 (27.0%) |
| Oxygen saturation | <95% |
427 152 (72.9%) |
|
|
≥95% |
158 503 (27.1%) |
| Diarrhoea | Yes |
155 385 (26.5%) |
|
|
No |
430 270 (73.5%) |
| Vomit | Yes |
118 270 (20.2%) |
|
|
No |
467 385 (79.8%) |
| Abdominal pain | Yes |
104 898 (17.9%) |
|
|
No |
480 757 (82.1%) |
| Fatigue | Yes |
212 913 (36.4%) |
|
|
No |
372 742 (63.6%) |
| Loss of smell | Yes |
144 563 (24.7%) |
|
|
No |
441 092 (75.3%) |
| Loss of taste | Yes |
146 228 (25.0%) |
|
|
No |
439 427 (75.0%) |
| Other symptoms | Yes |
264 850 (45.2%) |
|
|
No |
320 805 (54.8%) |
| Comorbidities (any) |
Yes |
389 743 (66.5%) |
|
|
No |
195 912 (33.5%) |
| Cardiopathy | Yes |
263 365 (45.0%) |
|
|
No |
322 290 (55.0%) |
| Hematologic disorder | Yes |
6056 (1.0%) |
|
|
No |
579 599 (99.0%) |
| Down syndrome | Yes |
1732 (0.3%) |
|
|
No |
583 923 (99.7%) |
| Hepatic disorder | Yes |
8532 (1.5%) |
|
|
No |
577 123 (98.5%) |
| Asthma | Yes |
46 334 (7.9%) |
|
|
No |
539 321 (92.1%) |
| Diabetes mellitus | Yes |
218 758 (37.4%) |
|
|
No |
366 897 (62.6%) |
| Neurological disorder | Yes |
60 654 (10.4%) |
|
|
No |
525 001 (89.6%) |
| Chronic respiratory disease | Yes |
65 293 (11.1%) |
|
|
No |
520 362 (88.9%) |
| Immunosuppressive disorder | Yes |
45 652 (7.8%) |
|
|
No |
540 003 (92.8%) |
| Renal disease | Yes |
67 667 (11.6%) |
|
|
No |
517 988 (88.4%) |
| Obesity | Yes |
111 219 (19.0%) |
|
|
No |
474 436 (81.0%) |
| Other comorbidities† | Yes |
236 839 (40.4%) |
|
|
No |
348 816 (59.6%) |
| Antiviral drug to treat the infection | Yes |
78 153 (13.3%) |
|
|
No |
507 502 (86.7%) |
| Need for intensive care unit | Yes |
212 067 (36.2%) |
|
|
No |
373 588 (63.8%) |
| Need for mechanical ventilatory support | No |
141 104 (24.1%) |
| No invasive |
318 032 (54.3%) |
|
|
|
Invasive |
126 519 (21.6%) |
| Discharge criterion | Laboratorial criterion |
548 600 (93.7%) |
|
|
Clinical criterion |
37 055 (6.3%) |
| Outcome | Clinical recovery |
366 517 (62.6%) |
|
|
Death |
219 138 (37.4%) |
| Length of hospital stay |
|
10.85 ± 11.91 d |
| Length of stay in the intensive care unit | 3.51 ± 7.25 d | |
COVID-19 – Coronavirus Disease 2019, N – number of individuals, SARS-CoV-2 – severe acute respiratory syndrome 2, % – percentage
*We retrieved the individuals’ data from the Brazilian Ministry of Health (https://opendatasus.saude.gov.br/) platform and corresponded to one year of the pandemic (from February 22, 2020, to April 04, 2021). We presented the data as the number of individuals (percentage) or mean ± standard deviation.
†Individuals who lived in an endemic region for Flu; †the “other comorbidities” category did not contain the other comorbidities described in the table.